Scarica l'app Stockscreener
22.59
0.22%
0.105
Precedente Chiudi:
$22.48
Aprire:
$22.44
Volume 24 ore:
104.81K
Relative Volume:
0.08
Capitalizzazione di mercato:
$1.97B
Reddito:
$23.38M
Utile/perdita netta:
$-155.22M
Rapporto P/E:
-10.31
EPS:
-2.19
Flusso di cassa netto:
$-134.36M
1 W Prestazione:
+6.47%
1M Prestazione:
+1.58%
6M Prestazione:
-0.92%
1 anno Prestazione:
-43.67%
Intervallo 1D:
$22.41
$22.75
Intervallo di 1 settimana:
$21.22
$23.06
Portata 52W:
$13.45
$44.42
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta IDYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
22.53 | 1.85B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.94 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.10 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
317.19 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
563.75 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.86 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada
Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN
Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
RBC Cuts Price Target on IDEAYA Biosciences to $30 From $57, Keeps Outperform, Speculative Risk - MarketScreener
Here's Why We're Watching IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - 富途牛牛
(IDYA) Long Term Investment Analysis - news.stocktradersdaily.com
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell Small Cap Comp Growth Index - MarketScreener
IDEAYA Biosciences: A Precision Oncology Play Gains Momentum with Russell 2000 Inclusion - AInvest
Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream - AInvest
IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year - AInvest
IDEAYA Biosciences Awards Major Stock Package Worth $2.1M to Strategic New Hire - Stock Titan
IDEAYA Biosciences Holds Annual Stockholders Meeting - TipRanks
Rhumbline Advisers Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by GAMMA Investing LLC - Defense World
Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Comments on IDYA FY2026 Earnings - Defense World
Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by California State Teachers Retirement System - Defense World
IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - PR Newswire
IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
IDEAYA Biosciences (IDYA) Grants Stock Options to New Employees | IDYA Stock News - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Nuveen Asset Management LLC - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $66.00 - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Consensus PT from Brokerages - Defense World
(IDYA) Proactive Strategies - news.stocktradersdaily.com
JP Morgan Raises Price Target for IDEAYA Biosciences (IDYA) | ID - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Buys 10,543 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Jane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Bank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
January 2026 Options Now Available For IDEAYA Biosciences - Nasdaq
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha
(IDYA) Investment Analysis - news.stocktradersdaily.com
FY2025 EPS Estimates for IDYA Cut by Cantor Fitzgerald - Defense World
Stifel Financial Corp Sells 3,834 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Dimensional Fund Advisors LP Has $8.91 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
16,769 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Raymond James Financial Inc. - Defense World
Brokers Issue Forecasts for IDYA Q2 Earnings - Defense World
Leerink Partnrs Has Bullish Estimate for IDYA Q2 Earnings - Defense World
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer - Barchart.com
Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus
IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 10.2% After Earnings Miss - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Mariner LLC - Defense World
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors - marketscreener.com
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.02%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):